Compare Ascendis Pharma A/S (ASND) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Amplify Transformational Data Sharing ETF — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Amplify Transformational Data Sharing ETF trades at $62.03. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BLOK | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $74.10 |
52-Week Low | $163.32 | $47.36 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BLOK trades at $62.66, down 1.2% with bearish technical signals from moving averages and oscillators. The stock faces resistance at $63 and support at $61. Recent news highlights the ETF's diversified blockchain economy exposure, though analyst sentiment has turned cautious due to increased bitcoin-linked exposure reducing diversification benefits.
Outlook remains mixed with technical weakness but strategic positioning in blockchain infrastructure. Key risks include crypto market volatility and reduced diversification. Investment opportunity exists for long-term exposure to blockchain technology growth, balanced against near-term technical headwinds and sector concentration concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
